Tesi etd-01072026-151355 |
Link copiato negli appunti
Tipo di tesi
Tesi di specializzazione (5 anni)
Autore
VETERE, GUGLIELMO
URN
etd-01072026-151355
Titolo
Phase II enrichment study of panitumumab re-treatment with or without trametinib in anti-EGFR-refractory RAS and BRAF wild-type metastatic colorectal cancer
Dipartimento
RICERCA TRASLAZIONALE E DELLE NUOVE TECNOLOGIE IN MEDICINA E CHIRURGIA
Corso di studi
ONCOLOGIA MEDICA
Relatori
relatore Prof. Cremolini, Chiara
correlatore Dott.ssa Antoniotti, Carlotta
correlatore Dott.ssa Antoniotti, Carlotta
Parole chiave
- anti-EGFR
- ctDNA
- mCRC
- panitumumab
- re-treatment
- trametinib
Data inizio appello
27/01/2026
Consultabilità
Non consultabile
Data di rilascio
27/01/2029
Riassunto
This thesis reports the clinical and translational results of a phase II enrichment study evaluating panitumumab re-treatment with or without trametinib in patients with RAS and BRAF wild-type metastatic colorectal cancer who developed resistance to prior anti-EGFR therapy. Patients were prospectively assigned to treatment cohorts based on the mutational profile of KRAS, NRAS, BRAF, EGFR ectodomain, and MAP2K1 detected in circulating tumor DNA (ctDNA) at screening. Participants received either panitumumab monotherapy or panitumumab combined with the MEK inhibitor trametinib, with optional crossover from monotherapy to combination treatment upon progression. The study integrates clinical outcomes with longitudinal ctDNA profiling and spatial transcriptomics to describe biological changes during anti-EGFR re-treatment and to inform future strategies in this setting.
File
| Nome file | Dimensione |
|---|---|
La tesi non è consultabile. |
|